The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
During a session at AACR 2026, NCI Director Anthony Letai, MD, PhD, said that despite a turbulent past year, the institute is stable and its mission unchanged.
We would like to inform you of an important update regarding the 4th SOHO-Israel Meeting & 10th International Davidoff Conference. In light of the current complexities in Israel, we have made the careful decision to postpone the conference. The event will now take place on November 19–20, 2026, instead of the originally scheduled dates of May 7–8, 2026.
At the AACR-Oncology Partnering event, Richard Pazdur, former FDA-OCE director discusses FDA morale, politics and AI shift.
Human intelligence will be more important than ever as artificial intelligence continues to proliferate throughout clinical care, according Yu Shyr, PhD, FAACR, chair of the Department of Biostatistics at Vanderbilt University Medical Center in Tennessee. Dr. Shyr was the keynote speaker to at the AACR Oncology Industry Partnering Event, which is being held April 16–17 in San Diego.
The US Food and Drug Administration (FDA) has granted Fast Track Designation to OPN-6602, an oral small-molecule EP300/CBP inhibitor, for patients with relapsed or refractory multiple
To access the SOHO Career Center click the following link.
